Abstracts tagged "diagnosis and medical management"

Abstract Number: 2673 • 2019 ACR/ARP Annual Meeting
Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
Alfred Mahr¹, Eric Hachulla ², Hubert de BOYSSON ³, Nassim Guerroui ⁴, Emmanuel Héron ⁵, Stéphane Vinzio ⁶, Jonathan Broner ⁷, François-Xavier Lapebie ⁸, Martin Michaud ⁹, Laurent Sailler ⁸, Thierry Zenone ¹⁰, Mohamed Djerad ¹¹, Mathieu Jouvray ¹², Emilie Shipley ¹³, Nathalie Tieulie ¹⁴, Isabelle Idier ¹⁵, Marc Paccalin ¹⁶ and Valérie Devauchelle Pensec ¹⁷, ¹Hospital Saint-Louis, University Paris Diderot, Paris, France, ²Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ³University Hospital of Caen, Caen, France, ⁴European Hospital of Marseille, Marseille, France, ⁵Quinze-Vingt Hospital, Paris, France, ⁶GHM Grenoble, Grenoble, France, ⁷University Hospital of Nîmes, Nîmes, France, ⁸University Hospital of Toulouse, Toulouse, France, ⁹Joseph Ducuing Hospital, Toulouse, France, ¹⁰Hospital of Valence, Valence, France, ¹¹Hospital of Nevers, Nevers, France, ¹²Hospital of Arras, Arras, France, ¹³Hospital of Dax, Dax, France, ¹⁴University Hospital of Nice, Nice, France, ¹⁵Chugai Pharma France, Paris La Défense, France, ¹⁶University Hospital of Poitiers, Poitiers, France, ¹⁷University Hospital of Brest, Brest, France
Background/Purpose: We have few real-world data on the natural history and care of patients with giant cell arteritis (GCA). The objective of this observational study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].